US Stock Movement: Liquidia surges on October 14th due to UTHR settlement and continued PAH sales

Liquidia Soars on October 14: Analysis

Keywords: UTHR settlement, PAH ongoing sales

1. On October 13, Liquidia reached a global settlement with United Therapeutics, resolving all six pending lawsuits between the parties. The net total payment is $380.7 million, to be paid in installments in 2026 and 2027.

2. On October 13, the company confirmed that YUTREPIA will continue to be used for pulmonary arterial hypertension (PAH) and maintain ongoing supply. The settlement requires the company to seek removal of the pulmonary hypertension due to interstitial lung disease (PH-ILD) indication from the product label and to cease promotion for this indication.

(Disclaimer: This content is generated by AI technology summarizing publicly available information. For reference only, not investment advice.)